智通财经APP讯,和铂医药-B(02142)发布截至2024年12月31日止年度业绩,该集团期内取得收入3810万美元,同比减少57.43%;年内溢利274.2万美元,同比减少87.95%;每股基本盈利0美元。
公告称,创新业务模式的实施推动了开支管理效率的大幅提升,继而令集团的研发成本从截至2023年12月31日止年度的4510万美元减少2410万美元或53.4%至截至2024年12月31日止年度的2100万美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.